Management of atheroslerosis for the next century - symptomaticand preventive therapy. Satellite symposium. Vienna, ATR, 1998/08/22.
Aim Guidelines on primary and secondary prevention of coronary heart disease (CHD) in Europe are intensively debated because of the potential financial impact of treating all patients at elevated CHD risk on the budget for pharmaceuticals.
In the present study we estimated the cost effectiveness of treating the largest possible number of patients with demonstrable evidence for treatment benefit for cholesterol-lowering drugs in the age group 45-65 years from the perspective of the social security system.
Methods The analysis is based on a model which approximates the discounted lifetime costs of all patients who presented themselves in 1996 to a German hospital for either primary or secondary events of CHD or who died from CHD in that year.
The costs of this cohort in 1996 and up to their projected end of life was estimated and included all direct and indirect costs (discount rate : 4%). Data for direct costs were generated from the Federal Bureau of Statistics, sickness funds, retirement funds, hospital admission data sources, primary care panel physician data and other sources.
Gender and age-specific unemployment rates were considered in calculating indirect costs.
Additionally, the effects on revenues and expenses for sickness funds and other parts of the social security system were estimated. (...)
Mots-clés Pascal : Cardiopathie coronaire, Hypercholestérolémie, Hydroxymethylglutaryl-CoA synthase, Oxo-acid-lyases, Carbon-carbon lyases, Lyases, Enzyme, Inhibiteur enzyme, Analyse coût efficacité, Economie santé, Allemagne, Europe, Chimiothérapie, Traitement, Prévention, Homme, Primaire, Secondaire, Lipide, Hypolipémiant, Appareil circulatoire pathologie, Métabolisme pathologie, Dyslipémie, Hyperlipoprotéinémie
Mots-clés Pascal anglais : Coronary heart disease, Hypercholesterolemia, Hydroxymethylglutaryl-CoA synthase, Oxo-acid-lyases, Carbon-carbon lyases, Lyases, Enzyme, Enzyme inhibitor, Cost efficiency analysis, Health economy, Germany, Europe, Chemotherapy, Treatment, Prevention, Human, Primary, Secondary, Lipids, Antilipemic agent, Cardiovascular disease, Metabolic diseases, Dyslipemia, Hyperlipoproteinemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0419025
Code Inist : 002B02N. Création : 22/03/2000.